Cardiol Therapeutics Locks Phase II ARCHER Trial Database
Ticker: CRDL · Form: 6-K · Filed: Jul 22, 2025 · CIK: 1702123
Sentiment: neutral
Topics: clinical-trial, biotech, milestone
TL;DR
Cardiol just locked its Phase II myocarditis trial data, analysis coming soon.
AI Summary
Cardiol Therapeutics Inc. announced on July 22, 2025, that it has achieved database lock for its Phase II ARCHER trial of CardiolRx™ in patients with acute myocarditis. This milestone signifies the completion of data collection for the trial, paving the way for data analysis and subsequent reporting of results.
Why It Matters
Database lock is a critical step in clinical trials, indicating that data collection is complete and analysis can begin, bringing the company closer to potential results for its acute myocarditis treatment.
Risk Assessment
Risk Level: medium — Clinical trial progress is a key driver for biotech companies, and the success or failure of this trial will significantly impact Cardiol Therapeutics.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- CardiolRx™ (product) — Investigational drug
- ARCHER Trial (trial) — Phase II clinical trial
- July 22, 2025 (date) — Announcement date
- acute myocarditis (condition) — Indication being studied
FAQ
What is the significance of the database lock for the ARCHER trial?
The database lock signifies the completion of data collection for the Phase II ARCHER trial, allowing for the commencement of data analysis and reporting of results.
What is Cardiol Therapeutics investigating with CardiolRx™?
Cardiol Therapeutics is investigating CardiolRx™ in a Phase II trial for patients with acute myocarditis.
When was the database lock announced?
The database lock was announced on July 22, 2025.
What is the name of the Phase II trial?
The Phase II trial is named the ARCHER trial.
What is the primary indication for the ARCHER trial?
The primary indication for the ARCHER trial is acute myocarditis.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 22, 2025 regarding Cardiol Therapeutics Inc. (CRDL).